
    
      The NexGen LPS-FLex Mobile Bearing Knee received FDA approval for commercial distribution in
      the US on December 10, 2007. The approval was in accordance with a "condition of approval" to
      perform a 10-year post approval study to evaluate the longer-term safety and effectiveness of
      the LPS-Flex Mobile Bearing Knee. The post approval study will consist of patients from the
      investigational device exemption study arm (Group 1) as well as patients who are eligible for
      a total knee replacement and have been chosen to receive the LPS-Flex Mobile Knee (Group 2).
      Group 1 will be followed through a total of 10 years from the date of surgery and has
      completed t his portion of the study. Group 2 will be followed through a total of 5 years
      from the date of surgery.
    
  